Home
Resources
Publications
Pharmacologic Therapy of Mycotic Keratitis

Pharmacologic Therapy of Mycotic Keratitis

Pranita Sahay, Deepali Singhal, Ritu Nagpal, Prafulla K Maharana, Marjan Farid, Rachel Gelman, Rajesh Sinha, Tushar Agarwal, Jeewan S Titiyal, Namrata Sharma

Surv Ophthalmol. May-Jun 2019;64(3):380-400.

PMID: 30797882

Abstract:

Mycotic keratitis continues to be an important cause of corneal blindness, especially in tropical and subtropical countries. The prognosis is poor compared with many other forms of keratitis because of the lack of effective antifungal drugs. The currently available antifungal drugs suffer from multiple drawbacks such as poor ocular penetration, unpredictable bioavailability, and adverse effects associated with systemic medications. Over the last decade, several new drugs and drug-delivery systems have been introduced in an attempt to improve the treatment outcomes. Thorough knowledge of the currently available antifungal drugs, their spectrum of action, and associated adverse effects is essential to deal with cases of mycotic keratitis. We discuss the pharmacologic properties and clinical use of the currently available antifungal drugs.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP7681938-B	Natamycin		7681-93-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: